Medincell, a pioneering biopharmaceutical company headquartered in France, focuses on the development of innovative long-acting injectable therapies. Founded in 2000, the company has made significant strides in the industry, particularly in the fields of mental health and chronic diseases. Medincell's proprietary technology platform, which enables the sustained release of active pharmaceutical ingredients, sets it apart from competitors. With a strong presence in Europe and expanding operations globally, Medincell is committed to addressing unmet medical needs through its core products, including its lead candidate for the treatment of schizophrenia. The company has garnered recognition for its unique approach to drug delivery, positioning itself as a leader in the biopharmaceutical sector. Medincell continues to advance its mission of improving patient outcomes through innovative therapeutic solutions.
How does Medincell's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Medincell's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Medincell reported total carbon emissions of approximately 5,000,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 776 kg CO2e, primarily from mobile combustion, while Scope 2 emissions totalled approximately 40,820 kg CO2e, all from purchased electricity. The most significant contribution came from Scope 3 emissions, which amounted to around 4,500,000 kg CO2e, with major sources including purchased goods and services (approximately 4,214,400 kg CO2e) and business travel (about 212,750 kg CO2e). In 2023, Medincell's emissions were lower, with total emissions of about 5,000,000 kg CO2e, including 12,860 kg CO2e from Scope 2 and significant Scope 3 emissions of approximately 4,800,000 kg CO2e. Notably, there were no reported Scope 1 emissions in 2023. Medincell has not set specific reduction targets or initiatives as part of their climate commitments, and there are no cascading emissions data from a parent company. The company is actively working to understand and manage its carbon footprint, but further details on reduction strategies or pledges are currently unavailable.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | 000 |
| Scope 2 | 8,380 | 0,000 | 0,000 | 0,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - | 0,000,000 | 0,000,000 |
Medincell's Scope 3 emissions, which decreased by 12% last year and decreased by approximately 12% since 2023, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 74% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medincell has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
